Coherus Oncology (CHRS) Net Income (2013 - 2026)
Coherus Oncology (CHRS) posted Net Income of -$1.4 million for Q1 2026, down 115.99% sequentially from $8.7 million in Q4 2025, and up 84.82% YoY from -$753158.2 in Q1 2025.
Coherus Oncology (CHRS) Net Income (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Net Income for 14 years, with the latest figure at -$1.4 million in Q1 2026.
- Quarterly Net Income rose 84.82% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $358.9 million (up 452.16% YoY) and the FY2025 annual result came in at $351.1 million, up 43.97% from the prior year.
- Net Income slipped to -$1.4 million in Q1 2026 per CHRS's latest filing, from $8.7 million in the prior quarter.
- Over five years, Net Income peaked at $342.6 million in Q2 2025 and troughed at -$96.1 million in Q1 2022.
- A 5-year average of $3.8 million and a median of -$9.2 million in 2025 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income plunged 124.9% in 2022, then soared 717.15% in 2025.
- Over 5 years, Net Income stood at -$58.9 million in 2022, then plunged by 35.3% to -$79.7 million in 2023, then soared by 94.22% to -$4.6 million in 2024, then soared by 289.09% to $8.7 million in 2025, then sank by 115.99% to -$1.4 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$1.4 million, $8.7 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -20.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.72 Mn |
| Mar 31, 2026 | -1.39 Mn |
| Dec 31, 2025 | 8.70 Mn |
| Sep 30, 2025 | 8.99 Mn |
| Jun 30, 2025 | 342.63 Mn |
| Mar 31, 2025 | -9.17 Mn |
| Dec 31, 2024 | -4.60 Mn |
| Sep 30, 2024 | 36.85 Mn |
| Jun 30, 2024 | 41.93 Mn |
| Mar 31, 2024 | 170.91 Mn |
| Dec 31, 2023 | -79.65 Mn |
| Sep 30, 2023 | -39.64 Mn |
| Jun 30, 2023 | -42.87 Mn |
| Mar 31, 2023 | -75.73 Mn |
| Dec 31, 2022 | -58.87 Mn |
| Sep 30, 2022 | -86.65 Mn |
| Jun 30, 2022 | -50.15 Mn |
| Mar 31, 2022 | -96.08 Mn |
| Dec 31, 2021 | -45.68 Mn |
| Sep 30, 2021 | -38.53 Mn |